GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Biogen Idec Inc (BIIB) [hlAlert]

Rating:
Buy BIIB
up 535.01 %

Dow Theory Forecasts picks Biogen Idec (BIIB) for 2009

Posted on: Saturday,  Feb 14, 2009  2:27 AM ET by The Stock Advisors Top Stocks For 2009

The Stock Advisors Top Stocks For 2009 rated Buy Biogen Idec Inc (NASDAQ: BIIB) on 01/08/2009, when the stock price was
$47.95. Since then, Biogen Idec Inc has gained 535.02% as of 01/07/2016's recent price of $304.49.
If you would have followed this The Stock Advisors Top Stocks For 2009's recommendation on BIIB, you would have gained 535.01% of your investment in 2555 days.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

Every year since 1983, thestockadvisors has polled the nation’s leading financial newsletter advisors asking them to select their favorite stocks for the coming year. In this year’s special report, 75 “best of breed” advisors have joined to provide you with the ultimate shopping list of trading and investing ideas for 2009. The stocks that are featured range from conservative, high quality blue chips to exciting home run speculations, for those willing to incur high risk in exchange for the potential to maximize upside gains. Importantly, readers should be certain that any stocks you consider meet your own investment strategy, time horizen and risk tolerance. As such, investors should view the 75 stocks in this report as a only as a starting place; do you own research, and continue to monitor any stocks that you may buy. Advisors are making their selections based on their current analysis of a company within the current market environment. But fundamentals change, and a stock that is now a favorite buy can quickly become a sell, based on future events.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/8/2009 12:00 AM Buy
None
47.95
as of 12/31/2009
1 Week up  27.81 %
1 Month up  42.24 %
3 Months up  32.16 %
1 YTD up  39.24 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy